Immuron Ltd — Regulatory Filings 2011

Feb 23, 2011

==> picture [193 x 41] intentionally omitted <==

ASX Release

24 February 2011

Immuron Limited ABN 80 063 114 045

Australian sales of Travelan[®] expected to increase

Corporate Details:

ASX Code: IMC

Directors

Chairman:

Prof. Colin Chapman Non-Executive Directors: Prof. Roy Robins-Browne Mr Simon Sallka Dr Elane Zelcer

Nycomed Pty Ltd, the Australian distributor of Travelan (our diarrhoea prevention product) has informed Immuron Limited its revenue forecasts for Travelan in the Australian market for 2011 are expected to increase 50 per cent on sales over the 2010 calendar year.

Following a successful launch by Nycomed in 2010, Travelan sales are expected to continue to grow rapidly and exceed 42,000 packs this year, demonstrating the early growth path for Travelan

Immuron and Nycomed are also advancing discussions to expand Travelan’s success into overseas markets.

Chief Executive Officer

Joe Baini

Chief Scientific Officer Dr Grant Rawlin

==> picture [102 x 66] intentionally omitted <==

Joe Baini Chief Executive Officer

Medical Director Prof. Yaron Ilan

Substantial Shareholder

Hadasit Medical Research 17.96%

For more information please contact:

Joe Baini – Chief Executive Officer Immuron Ltd Tel: +61 3 9018 4880 Email: joe@immuron.com

Emma Power - Media Relations Monsoon Communications Tel: 61 3 9620 3333 or 61 (0)419 149 525

About Immuron Limited

Contact Details:

Immuron Limited Level 1 39 Leveson Street North Melbourne VIC 3051 Australia

Immuron is a biopharmaceutical company focused on oral immunotherapy using dairyderived polyclonal antibody products for humans. Immuron is a uniquely positioned biotechnology company with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited.

Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as type II diabetes and fatty liver (NASH), and the prevention of influenza.

Immuron has one product in the market, Travelan, for use in preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and the Universities of Melbourne and Monash (Australia).

Tel: +61 (0)3 9018 4880 www.immuron.com

.